ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer
February 15, 2025At 2025 ASCO GU, Prof. Xinan Sheng disclosed phase II trial data of DV + Toripalimab for HER2 - expressing MIBC, showing high pCR and manageable safety. -
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
June 15, 2021Asieris today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with MIBC.
Pharma Sources Insight January 2025
